Jose Silva

Pleasure to be with you, Jose. So today we're going to be discussing mainly testosterone therapy and prostate cancer. So since you've been working with this, you've been a pioneer in this field, can you tell a little bit of the story in terms of the testosterone evaluation, labs and symptoms? How has it changed the way we treat testosterone in the past 30 years?

Pleasure to be with you, Jose. So today we're going to be discussing mainly testosterone therapy and prostate cancer. So since you've been working with this, you've been a pioneer in this field, can you tell a little bit of the story in terms of the testosterone evaluation, labs and symptoms? How has it changed the way we treat testosterone in the past 30 years?

Pleasure to be with you, Jose. So today we're going to be discussing mainly testosterone therapy and prostate cancer. So since you've been working with this, you've been a pioneer in this field, can you tell a little bit of the story in terms of the testosterone evaluation, labs and symptoms? How has it changed the way we treat testosterone in the past 30 years?

And 30 years ago when you started, when you finished residency, how was the landscape at that moment? I mean, how did you say, okay, I'm going to start treating patients or men with testosterone?

And 30 years ago when you started, when you finished residency, how was the landscape at that moment? I mean, how did you say, okay, I'm going to start treating patients or men with testosterone?

And 30 years ago when you started, when you finished residency, how was the landscape at that moment? I mean, how did you say, okay, I'm going to start treating patients or men with testosterone?

And this was still a random biopsy? What were we doing at the time?

And this was still a random biopsy? What were we doing at the time?

And this was still a random biopsy? What were we doing at the time?

And so, Ryan, in 2024, how's that treatment evolve since 2004 in terms of injections, pills, or what were you doing first and then what are you doing now? Just go through the thought process of how you decide where to allocate each patient.

And so, Ryan, in 2024, how's that treatment evolve since 2004 in terms of injections, pills, or what were you doing first and then what are you doing now? Just go through the thought process of how you decide where to allocate each patient.

And so, Ryan, in 2024, how's that treatment evolve since 2004 in terms of injections, pills, or what were you doing first and then what are you doing now? Just go through the thought process of how you decide where to allocate each patient.

And doctor, you mentioned that the high peaks don't cause prostate cancer. We know that. But in terms of possible side effects, we know that the pills, they say that the peaks are less, the gels, the peaks are less, doing low doses of injectables versus the pellets, which you will get a higher peak. Is that true? Or what are you looking for when you start a treatment for testosterone?

And doctor, you mentioned that the high peaks don't cause prostate cancer. We know that. But in terms of possible side effects, we know that the pills, they say that the peaks are less, the gels, the peaks are less, doing low doses of injectables versus the pellets, which you will get a higher peak. Is that true? Or what are you looking for when you start a treatment for testosterone?

And doctor, you mentioned that the high peaks don't cause prostate cancer. We know that. But in terms of possible side effects, we know that the pills, they say that the peaks are less, the gels, the peaks are less, doing low doses of injectables versus the pellets, which you will get a higher peak. Is that true? Or what are you looking for when you start a treatment for testosterone?

And in terms of side effects, I mean, it's mainly the same profile for all of them or, I mean, for example, blood clots. I mean, is that something to be concerned?

And in terms of side effects, I mean, it's mainly the same profile for all of them or, I mean, for example, blood clots. I mean, is that something to be concerned?

And in terms of side effects, I mean, it's mainly the same profile for all of them or, I mean, for example, blood clots. I mean, is that something to be concerned?

And doctor, let's go back to 2004. You just published the journal that essentially doesn't cause cancer. So how does you evolve into, hey, we have patients with cancer or prostatectomy, low testosterone, how do you start treating them with confidence? Or again, it was more or less same situation as when you were treating them before, like just very cautious. How did that process started?

And doctor, let's go back to 2004. You just published the journal that essentially doesn't cause cancer. So how does you evolve into, hey, we have patients with cancer or prostatectomy, low testosterone, how do you start treating them with confidence? Or again, it was more or less same situation as when you were treating them before, like just very cautious. How did that process started?